Ajooni Biotech Limited — Updates, 06-01-2025: Press Release

Ajooni Biotech Limited will issue up to 5 Crores convertible warrants at ₹9 each, raising ₹45 Crores from both promoters and non-promoters, which includes various investment funds and corporates. This step follows the approval by the Board of Directors to increase the company’s Authorized Share Capital from ₹40 Crores to ₹50 Crores. The convertible warrants are designed to enhance the company's capital structure and provide financial flexibility for future initiatives. This strategic move is expected to strengthen the company’s foundation and support its growth ambitions, with management expressing confidence in expanding market presence and driving shareholder value. In FY24, Ajooni Biotech reported revenue of ₹82.30 Crores, EBITDA of ₹4.43 Crores, and a net profit of ₹2.17 Crores.